The effect of FAAH, MAGL, and Dual FAAH/MAGL inhibition on inflammatory and colorectal distension-induced visceral pain models in Rodents

Neurogastroenterology and Motility

Volumn 27, Issue 7, 2015, Pages 936-944

  Sakin, Y S ^a   Dogrul, A ^a   Ilkaya, F ^b   Seyrek, M ^a   Ulas, U H ^a   Gulsen, M ^a   Bagci, S ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ONDOKUZ MAYIS UNIVERSITY   (Turkey)

Author keywords

Acetic acid writhing test; Colorectal distension; FAAH inhibitor; FAAH MAGL dual inhibitors; MAGL inhibitor; Visceral pain

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [BIS(1,3 BENZODIOXOL 5 YL)HYDROXYMETHYL] 1 PIPERIDINECARBOXYLIC ACID 4 NITROPHENYL ESTER; ACETIC ACID; ACYLGLYCEROL LIPASE; ACYLGLYCEROL LIPASE INHIBITOR; AMIDOHYDROLASE INHIBITOR; ESTERASE INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; JZL 195; PF 3845; UNCLASSIFIED DRUG; 1,3 BENZODIOXOLE DERIVATIVE; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; AMIDASE; CARBAMIC ACID DERIVATIVE; CYCLOHEXANOL DERIVATIVE; FATTY-ACID AMIDE HYDROLASE; JZL195; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; COLON; COLON DILATATION; COLORECTAL DISTENSION; CONTROLLED STUDY; ENZYME INHIBITION; EVOKED RESPONSE; EVOKED SOMATOSENSORY RESPONSE; INFLAMMATION; MALE; MOUSE; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; VISCERAL PAIN; VISCEROMOTOR RESPONSE; WRITHING TEST; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DRUG EFFECTS; METABOLISM; PAIN MEASUREMENT; PATHOPHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

AMIDOHYDROLASES; ANIMALS; BENZODIOXOLES; CARBAMATES; COLON; CYCLOHEXANOLS; INFLAMMATION; MALE; MICE; MICE, INBRED BALB C; MONOACYLGLYCEROL LIPASES; PAIN MEASUREMENT; PIPERAZINES; PIPERIDINES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; VISCERAL PAIN;

EID: 84931576945     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/nmo.12563     Document Type: Article

References (52)

1. Cervero F, Laird JM. Visceral pain Lancet 1999; 353: 2145-8.
2. Collett B. Visceral pain: the importance of pain management services. Br J Pain 2013; 7: 6-7.
3. Duncan M, Davison JS, Sharkey KA. Endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22: 667-83.
4. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Nonpsychotropic plant cannabinoids: new therapeutic opportunities for an ancient herb. Trends Pharmacol Sci 2009; 30: 515-27.
5. Serpell M, Ratcliffe S, Hovorka J, Schofield M, Taylor L, Lauder H, Ehler E. A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment. Eur J Pain 2014; 18: 999-1012.
6. Snedecor SJ, Sudharshan L, Cappelleri JC, Sadosky A, Mehta S, Botteman M. Systematic review and comparison of pharmacologic therapies for neuropathic pain associated with spinal cord injury. J Pain Res 2013; 6: 539-47.
7. Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain 2013; 14: 136-48.
8. Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract 2011; 11: 353-68.
9. Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex(R) (nabiximols). MultScler 2012; 18: 219-22.
10. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, Gallo L, Capasso F et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 2012; 166: 1444-60.
11. Brusberg M, Arviddson S, Kang D, Larsson H, Lindström E, Martinez V. CB1 receptor mediate the analgesic effects of cannabinoids on colorectal distension-induced visceral pain in rodents. J Neurosci 2009; 29: 1554-64.
12. Fioramonti J, Bueno L. Role of cannabinoid receptors in the control of gastrointestinal motility and perception. Expert Rev Gastroenterol Hepatol 2008; 2: 385-97.
13. Kikuchi A, Ohashi K, Sugie Y, Sugimoto H, Omura H. Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity. J Pharmacol Sci 2008; 106: 219-24.
14. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006; 18: 949-56.
15. Izzo AA. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 2007; 19: 704-8.
16. ® (tetrahydrocannabidiol + cannabidiol), an endocannabinoid system modulator: basic features and main clinical data. Exp Rev Neurother 2011; 11: 15-9.
17. Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008; 57: 1140-55.
18. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-6.
19. Ahn K, Johnson DS, Mileni M, Beidler D, Long JZ, McKinney MK, Weerapana E, Sadagopan N et al. Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol 2009; 16: 411-20.
20. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
21. Long JZ, Nomura DK, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A 2009; 106: 20270-5.
22. Anderson WB, Gould MJ, Torres RD, Mitchell VA, Vaughan CW. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model. Neuropharmacology 2014; 81: 224-30.
23. Fichna J, Sal aga M, Stuart J, Saur D, Sobczak M, Zatorski H, Timmermans JP, Bradshaw HB et al. Selective inhibition of FAAH produces antidiarrheal and antinociceptive effect mediated by endocannabinoids and cannabinoid-like fatty acid amides. Neurogastroenterol Motil 2014; 26: 470-81.
24. Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 2009; 000: 31-74.
25. Jones RC 3rd, Gebhart GF. Models of visceral pain: colorectal distension (CRD). Curr Protoc Pharmacol 2004; Chapter 5: Unit 5.36.
26. Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudoaffective reflexes in the rat. Brain Res 1988; 450: 153-69.
27. Christianson JA, Gebhard GF. Assessment of colon sensitivity by luminal distension in mice. Nat Protoc 2007; 2: 2624-31.
28. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, Orlando P, Battista G et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 2013; 85: 1306-16.
29. Booker L, Naidu PS, Razdan RK, Mahadevan A, Lichtman AH. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Drug Alcohol Depend 2009; 105: 42-7.
30. Miller LL, Picker MJ, Umberger MD, Schmidt KT, Dykstra LA. Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. J Pharmacol Exp Ther 2012; 342: 177-87.
31. Klooker TK, Leliefeld KE, Van Den Wijngaard RM, Boeckxstaens GE. The cannabinoid receptor agonist delta-9-tetrahydrocannabinol does not affect visceral sensitivity to rectal distension in healthy volunteers and IBS patients. Neurogastroenterol Motil 2011; 23: 30-5.
32. Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister AR. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007; 293: 137-45.
33. Wong BS, Camilleri M, Busciglio I, Carlson P, Szarka LA, Burton D, Zinsmeister AR. Pharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndrome. Gastroenterology 2011; 141: 1638-47.
34. Cravatt BF, Lichtman AH. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003; 7: 469-75.
35. Piomelli D. The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 2005; 6: 672-9.
36. Jonsson KO, Holt S, Fowler CJ. The endocannabinoid system: current pharmacological research and therapeutic opportunities. Basic Clin Pharmacol Toxicol 2006; 98: 124-34.
37. Koutek B, Prestwich GD, Howlett AC, Chin SA, Salehani D, Akhavan N, Deutsch DG. Inhibitors of arachidonylethanolamide hydrolysis. J Biol Chem 1994; 269: 22937-40.
38. Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P et al. Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J Pharmacol Exp Ther 2011; 338: 114-24.
39. Booker L, Kinsey SG, Abdullah RA, Blankman JL, Long JZ, Ezzili C, Boger DL, Cravatt BF et al. The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice. Br J Pharmacol 2012; 165: 2485-96.
40. Clapper JR, Moreno-Sanz G, Russo R, Guijarro A, Vacondio F, Duranti A, Tontini A, Sanchini S et al. Anandamide suppresses pain initiation through a peripheral endocannabinoid mechanism. Nat Neurosci 2010; 13: 1265-70.
41. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 2006; 147: 281-8.
42. Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice. Pharmacol Biochem Behav 2011; 99: 718-25.
43. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J Pharmacol Exp Ther 2010; 334: 182-90.
44. Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 2004; 109: 319-27.
45. Chang L, Luo L, Palmer JA, Sutton S, Wilson SJ, Barbier AJ, Breitenbucher JG, Chaplan SR et al. Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br J Pharmacol 2006; 148: 102-13.
46. Long JZ, Li W, Booker L, Burston JJ, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009; 5: 37-44.
47. Schlosburg JE, Blankman JL, Long JZ, Nomura DK, Pan B, Kinsey SG, Nguyen PT, Ramesh D et al. Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system. Nat Neurosci 2010; 13: 1113-9.
48. Desroches J, Guindon J, Lambert C, Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008; 155: 913-24.
49. Guindon J, Guijarro A, Piomelli D, Hohmann AG. Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 2011; 163: 1464-78.
50. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH. Block-ade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 2009; 330: 902-10.
51. Galdino G, Romero TR, Silva JF, Aguiar DC, de Paula AM, Cruz JS, Parrella C, Piscitelli F et al. The endocannabinoid system mediates aerobic exercise-induced antinociception in rats. Neuropharmacology 2014; 77: 313-24.
52. Guindon J, Lai Y, Takacs SM, Bradshaw HB, Hohmann AG. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol Res 2013; 67: 94-109.